Grants and Contributions:
Title:
EUREKA - Development of a Macrocyclic Inhibitor Against the Zika and Dengue Virus NS2B-NS3 Proteases
Agreement Number:
907552
Agreement Value:
$350,000.00
Agreement Date:
Jun 1, 2018 - Mar 31, 2020
Description:
This project is focused on discovering a candidate ready for entry into formal regulatory preclinical development for the prevention and treatment of flavivirus infections by blocking an enzyme vital to the viral lifecycle with a new type of chemical structure to address the significant worldwide threat posed by these pathogens.
Organization:
National Research Council Canada
Expected Results:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Location:
Montreal, Quebec, CA H4S 1Z9
Reference Number:
172-2018-2019-Q1-907552
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
829528975
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Amendment Date
Jan 28, 2019
Recipient's Legal Name:
Cyclenium Pharma Inc
Federal Riding Name:
Saint-Laurent
Federal Riding Number:
24068
Program:
Eureka/Eurostar
Program Purpose:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Coverage:
EUREKA is a leading facilitator of innovation, providing a proven platform for international R&D&I cooperation.
NAICS Code:
54171
Amendments: